F-1/A: PomDoctor Files IPO Amendment Amidst Going Concern Doubts

PomDoctor Limited, a Cayman Islands holding company operating an online medical services platform in China, filed an amendment for its initial public offering of 5,000,004 American Depositary Shares, despite auditors expressing substantial doubt about its ability to continue as a going concern.

Summary

• PomDoctor Limited is a Cayman Islands holding company with primary operations in China through its Variable Interest Entity (VIE), Guangzhou Qilekang Digital Health Medical Technology Co., Ltd., and its subsidiaries.
• The company is preparing for an initial public offering (IPO) of 5,000,004 American Depositary Shares (ADSs) on the Nasdaq Global Market under the symbol POM, with an anticipated price range of US$4.00 to US$6.00 per ADS.
• The IPO is expected to generate net proceeds of approximately US$21.4 million, or US$24.9 million if the underwriters' over-allotment option is fully exercised.
• Proceeds are planned for supply chain stocking (35%), departmental and geographic expansion (25%), working capital (20%), research and development (10%), and general corporate purposes.
• The company reported net revenues of RMB304.9 million in 2023 and RMB342.6 million (US$46.9 million) in 2024, an increase of 12.4%.
• Net losses were RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024, with the net loss rate decreasing from 12.0% to 11.0%.
• Operating cash flows were negative RMB45.8 million in 2023 and negative RMB16.1 million (US$2.2 million) in 2024.
• Working capital deficit increased from RMB112.6 million in 2023 to RMB141.6 million (US$19.4 million) in 2024.
• The independent auditor expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and significant working capital deficit.
• The company operates a dual-class share structure, with Chairman and CEO Mr. Zhenyang Shi holding 76.0% of the aggregate voting power post-IPO, making it a controlled company under Nasdaq rules.
• PomDoctor is a leading online medical services platform for chronic diseases in China, ranking sixth in the Internet hospital market by contracted doctors in 2022.
• As of December 31, 2024, the platform had over 214,217 contracted doctors and 699,338 transacting patients, issuing approximately 3.13 million prescriptions.
• The company achieved a retention rate for mature doctors of 99.4% in both 2023 and 2024, and a 90-day patient repurchase rate of 63.7% and 66.2% respectively.
• Average revenue per paying patient increased from RMB714 in 2023 to RMB766 in 2024.
• Three material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel, inadequate financial reporting policies, and lack of proper system logical access security and change management.
• The company has completed required filings with the CSRC for this offering, with results published on January 17, 2025.

Sentiment

Score: 3

Explanation: The company shows strong operational growth in key metrics like patient and doctor engagement, and revenue. However, the explicit 'going concern' warning from auditors, persistent net losses, increasing working capital deficit, and identified material weaknesses in internal controls significantly overshadow these positives, indicating substantial financial instability and high risk for investors.

Positives

• Net revenues increased by 12.4% from RMB304.9 million in 2023 to RMB342.6 million (US$46.9 million) in 2024.
• Net loss rate decreased from 12.0% in 2023 to 11.0% in 2024, indicating improved efficiency despite continued losses.
• Net cash used in operating activities significantly improved from RMB45.8 million in 2023 to RMB16.1 million (US$2.2 million) in 2024.
• The company is a leading online medical services platform for chronic diseases in China, ranking sixth by contracted doctors in 2022.
• Cumulative contracted doctors stabilized at over 212,800 as of December 31, 2024, with 85,675 doctors issuing prescriptions in 2024.
• Transacting patients increased from 654,817 in 2023 to 699,338 in 2024.
• High retention rate for mature doctors (99.4% in 2023 and 2024) and a strong 90-day patient repurchase rate (63.7% in 2023, 66.2% in 2024) demonstrate strong user stickiness.
• Average revenue per paying patient increased from RMB714 in 2023 to RMB766 in 2024.
• The company has a well-established pharmaceutical supply chain with 42,493 SKUs as of December 31, 2024, including 13,267 prescription drugs.
• Possesses cutting-edge platform technology with 77 software copyrights, five patents, and two patent applications.
• Experienced management team with an average of 17 years of industry experience, validated by investments from industry leaders and institutional investors.
• Successfully completed the required CSRC filings for its overseas listing on January 17, 2025.
• Obtained online medical insurance payment qualification from Guangzhou Municipal Medical Security Bureau, with plans to expand this service.

Negatives

• Incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024.
• Experienced negative cash flows from operating activities of RMB45.8 million in 2023 and RMB16.1 million (US$2.2 million) in 2024.
• Working capital deficit increased from RMB112.6 million in 2023 to RMB141.6 million (US$19.4 million) in 2024.
• The independent auditor expressed substantial doubt about the company's ability to continue as a going concern.
• Identified three material weaknesses in internal control over financial reporting, indicating significant deficiencies.
• High reliance on a limited number of key suppliers, with one supplier accounting for 39.1% of total purchases in 2024.
• The gross profit margin of the Internet hospital segment decreased from 50.1% in 2023 to 42.7% in 2024, mainly due to increased online pharmacy sales of lower-margin products.
• Significant advertising expenses incurred in the past (RMB221.0 million in 2020-2021) which may not be cost-effective.
• Reliance on Variable Interest Entity (VIE) structure in China, which carries substantial uncertainties regarding interpretation and application of PRC laws and potential government intervention.
• Dual-class voting structure and concentrated ownership by Mr. Zhenyang Shi (76.0% voting power) limit the ability of other shareholders to influence corporate matters.
• No current plan to distribute earnings or settle amounts owed under VIE agreements in the foreseeable future, and no dividends or distributions made to U.S. investors to date.
• Not in full compliance with PRC labor laws and regulations regarding social insurance and housing provident fund contributions for some employees, potentially leading to penalties.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring net losses, negative operating cash flows, and significant working capital deficit.
• Failure to maintain customer trust in the ecosystem could severely damage reputation and brand.
• Early stage of development in an emerging and dynamic Internet + healthcare industry, with historical results not indicative of future performance.
• Inability to compete effectively in an increasingly competitive PRC Internet healthcare market.
• Improper use or disclosure of large amounts of generated and processed data could harm reputation and business.
• Incurrence of operating losses in the future and inability to achieve or maintain profitability.
• Failure of solutions to drive customer engagement or provide superior customer experience could materially and adversely affect business and reputation.
• Failure to properly manage and create value for various participants in the healthcare value chain may materially and adversely affect business.
• The digital healthcare market is immature and volatile; slow development or failure to drive user engagement could harm business growth.
• Failure to attract or retain sufficient users or medical professionals for online healthcare services.
• Potential medical liability claims in connection with online healthcare services, with no insurance covering medical malpractice claims for doctors on the platform.
• Subject to penalties or disputes for failure to manage doctors on the platform in compliance with PRC regulations.
• Business involves the sale of prescription drugs, which is subject to stringent scrutiny and evolving regulations in China.
• Failure to develop existing information infrastructure and technologies or recoup investments, and inability to innovate or adapt to changing user requirements.
• Self-developed technologies are complex and may contain undetected errors or not operate properly.
• Failure to maintain optimal inventory levels could increase operating costs or lead to unfulfilled customer orders.
• Liability for content available in the ecosystem that is alleged to be factually incorrect, socially destabilizing, obscene, defamatory, libelous, or otherwise unlawful.
• Reliance on a limited number of key suppliers, posing risks of delivery delays, quality issues, or unavailability of alternatives.
• Lack of requisite approvals, licenses, or permits applicable to the business, or changes in regulatory interpretation, could have a material adverse effect.
• Subject to a variety of laws and obligations regarding data protection, with uncertainties in interpretation and implementation, potentially leading to fines or sanctions.
• Potential for litigation, other legal or administrative disputes, and proceedings that may materially and adversely affect reputation, business, financial condition, or results of operations.
• Insufficient insurance coverage for business risks could expose the company to significant costs and business disruptions.
• Inability to prevent unauthorized use of intellectual property could harm business and competitive position.
• Security breaches and attacks against systems and network, and failure to protect confidential information, could damage reputation and adversely affect business.
• User growth and activity on mobile devices depend on effective use of mobile operating systems, networks, and standards not controlled by the company.
• Operations depend on the performance of Internet infrastructure and fixed telecommunications networks in China, as well as mobile operating systems and networks.
• Inability to conduct marketing activities cost-effectively and limitations in promoting healthcare-related services and products.
• Trading in securities may be prohibited under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect the auditor for two consecutive years.
• If the PRC government deems the VIE contractual arrangements non-compliant with foreign investment restrictions, severe penalties or relinquishment of interests could occur.
• Reliance on contractual arrangements with the VIE may not be as effective as direct ownership in providing operational control.
• Failure by the VIE or its shareholders to perform obligations under contractual arrangements could have a material adverse effect.
• Potential conflicts of interest with VIE shareholders could materially and adversely affect business and financial condition.
• Contractual arrangements may not be enforceable under PRC laws, limiting effective control over the VIE.
• Reliance on dividends and other distributions from PRC subsidiaries, which may be limited by PRC laws and regulations.
• PRC regulation of loans and direct investment by offshore holding companies may delay or prevent funding to PRC entities.
• Contractual arrangements may be subject to scrutiny by PRC tax authorities, potentially leading to additional taxes.
• Current corporate structure and business operations may be affected by the Foreign Investment Law.
• Loss of ability to use licenses, permits, and assets held by the VIE if the VIE declares bankruptcy or undergoes liquidation.
• Changes in China's or global economic, political, or social conditions or government policies could have a material adverse effect.
• Significant oversight and discretion of PRC governmental authorities over business operations could result in material adverse changes.
• Uncertainties with respect to the enforcement of laws and changes in laws and regulations in China could adversely affect the company.
• Approval or filing of the CSRC or other PRC regulatory agencies may be required for this offering and future capital raising activities.
• Difficulty for overseas regulators to conduct investigations or collect evidence within China.
• A severe or prolonged downturn in the global economy could materially and adversely affect business.
• No public market for shares or ADSs prior to this offering, leading to potential volatility and inability to resell at or above the offering price.
• Dual-class voting structure limits ability to influence corporate matters and could discourage change of control transactions.
• Techniques employed by short sellers may drive down the market price of ADSs.
• No expectation to pay dividends in the foreseeable future, requiring reliance on price appreciation for investment return.
• Immediate and substantial dilution for new investors due to offering price being substantially higher than net tangible book value per share.
• Substantial future sales or perceived potential sales of ADSs could cause the price to decline.
• Anti-takeover provisions in memorandum and articles of association could have an adverse effect on shareholder rights.
• Voting rights of ADS holders are limited by the terms of the deposit agreement.
• ADS holders may not receive cash dividends if the depositary deems it impractical.
• Limitations on transfer of ADSs.
• Dilution of holdings due to future equity issuance and inability to participate in rights offerings.
• Difficulties in protecting interests through U.S. courts due to incorporation under Cayman Islands law and operations in China.
• Certain judgments obtained against the company by shareholders may not be enforceable.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to significant adverse tax consequences for U.S. investors.
• Undetermined specific use for a portion of net proceeds from the offering, allowing management discretion.

Future Outlook

PomDoctor plans to continue recruiting quality doctors and attracting more patient users, expand its presence in key Chinese cities and provinces, enhance supply chain capabilities, and invest in research and development to improve technology. The company also aims to explore new patient acquisition channels through B2B collaborations, utilize accumulated big data to empower the industry, and expand its chronic disease management expertise to more medical areas. The company expects to achieve continuing growth in its Internet hospital business and anticipates clearer access to the national health insurance system in other areas as the Chinese government explores integration possibilities.

Management Comments

• Our mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses.
• Our vision is to become the most trustworthy medical and healthcare services platform.
• We strategically chose to focus on chronic diseases because they require ongoing medical attention, leading to inelastic demand for frequent follow-up visits and drug purchases, which benefits platforms maintaining long-term doctor-patient relationships.
• We believe that doctors are the most important resource in the medical services industry, hence our open Internet hospital business model focuses on serving them.
• Our patients were mainly sourced by doctors via existing patient-doctor relationships, their mutual trust is also transferred online, which translates into greater user stickiness on both ends and allows for great monetization potential.
• We do not expect to launch similar advertising campaigns as the Focus Media collaboration in the future, and will assess marketing effectiveness continuously based on web traffic, conversion rates, and ROI.
• We are currently implementing a number of measures to address the material weaknesses identified in our internal control over financial reporting, including hiring personnel, engaging consultants, and enhancing policies.
• Our liquidity is based on our ability to generate cash from operating activities, debt financing and capital contributions from our shareholders to fund its general operations and capital expansion needs.
• We are working to improve our liquidity and capital sources mainly through borrowing from related parties and financial institutions.

Industry Context

PomDoctor operates in China's rapidly expanding digital health and wellness market, which is projected to grow from RMB540.7 billion in 2022 to RMB1,525.9 billion in 2027, representing a CAGR of approximately 23.1%. The industry is driven by increasing penetration of digital medical services, innovation in digital health technology, favorable government policies promoting 'Internet+ Medical Health', growing health awareness, and the transition of hospitals and pharmacies from offline to online. The company's focus on chronic disease management aligns with a significant market need, as the patient pool for non-communicable diseases is drastically increasing, leading to a projected market size of RMB10,322.6 billion by 2027. PomDoctor ranks sixth in China's Internet Hospital Market by contracted doctors, indicating a strong competitive position, particularly in chronic disease management where it has achieved high doctor retention and patient repurchase rates.

Comparison to Industry Standards

• PomDoctor ranks sixth in China's Internet hospital market measured by the number of contracted doctors in 2022, according to Frost & Sullivan, indicating a strong competitive position.
• The company's retention rate for mature doctors of 99.4% in 2023 and 2024 is described as 'top-level' within the industry, suggesting performance superior to many competitors.
• The 90-day patient repurchase rate of 63.7% (2023) and 66.2% (2024) is highlighted as encouraging for chronic disease management, implying a strong performance metric for user stickiness in this specific segment.
• The company's storage of 42,493 SKUs as of December 31, 2024, including 13,267 prescription drugs, is compared favorably to a traditional public hospital which 'normally only has 1,000 to 3,000 SKUs', demonstrating a broader product offering.
• The average inventory turnover days of the top 5 offline pharmacies in China in 2022 were 87.8 days, compared with 26.3 days in the United States, highlighting a general industry inefficiency that digital platforms like PomDoctor aim to address, though specific comparison of PomDoctor's turnover days is not provided.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal or administrative proceedings.
• May from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business, including medical disputes, fraud, misconduct, sales and user services, and data protection.

Related Party Transactions

• Loans from Zhenyang Shi (CEO) to the company: RMB129.5 million (2023) and RMB135.7 million (US$18.6 million) (2024) at 4.90% annual interest, due December 31, 2026.
• Amounts due to Zhenyang Shi: RMB28.7 million (2023) and RMB25.7 million (US$3.5 million) (2024).
• Guangzhou Aixiangbao Investment Limited Liability Partnership (wholly-owned by Zhenyang Shi) assumed RMB221.0 million advertising liability from Focus Media on behalf of the company, with repayment to Aixiangbao not required for five years and then only by non-cash method (due August 10, 2026, non-interest bearing).
• Loans from Li Xu (CFO, CEO's spouse) to the company: RMB5.0 million (2023) and RMB1.5 million (US$0.2 million) (2024), including a RMB3.3 million loan at 8.88% due October 18, 2025, and non-interest bearing loans due on demand.
• Amounts due from Li Xu: RMB99,610 (US$13,646) (2024).
• Loans from Aihua Peng (close relative of a shareholder's management) to the company: RMB4.8 million (2023) and RMB4.0 million (US$0.6 million) (2024) at 20.00% annual interest, due on demand.
• Amounts due to Aihua Peng: RMB6.0 million (2023) and RMB6.9 million (US$0.9 million) (2024).
• Amounts due from Wanmei Shi (CEO's sister): RMB24,333 (2023) and nil (2024).
• Loans from Wanmei Shi: RMB21,000 (US$2,887) (2024) due on demand, non-interest bearing.
• Amounts due to Wanmei Shi: RMB100,000 (2023) and RMB75,667 (US$10,366) (2024).
• Loans from Guoji Luo (management) to the company: RMB2.0 million (2023) and RMB0.8 million (US$0.1 million) (2024), interest-free, due on demand or December 31, 2024.
• Amounts due to Guoji Luo: RMB44,089 (US$6,040) (2023 & 2024).
• Loans from Dexiang Wei (management) to the company: RMB810,045 (2023) and RMB339,450 (US$46,504) (2024), interest-free, due on demand or December 31, 2024.
• Amounts due to Dexiang Wei: RMB56,533 (2023) and RMB66,533 (US$9,115) (2024).
• Loans from Yongan Zhong (management) to the company: RMB2,685 (US$368) (2023 & 2024) due on demand, non-interest bearing.
• Amounts due to Yongan Zhong: RMB1,200 (US$164) (2023 & 2024).
• Amounts due from Guangzhou Zhiyao Cloud Technology Co., Ltd. (controlled by management): RMB778,584 (2023) and RMB819,977 (US$112,336) (2024).
• Drug sales to Guangzhou Zhiyao Cloud Technology Co., Ltd.: RMB123,073 (2023) and RMB1.2 million (US$0.2 million) (2024).
• Accounts receivable from Guangzhou Zhiyao Cloud Technology Co., Ltd.: RMB424,259 (US$58,123) (2024).
• Guarantees provided by Zhenyang Shi, Li Xu, Wanmei Shi, Guoji Luo, Dexiang Wei, Yongan Zhong, and other management members for various bank and third-party loans.

Stakeholder Impact

• **Shareholders (Existing & New):** Face significant dilution from the IPO. Existing shareholders will experience immediate and substantial dilution. The dual-class voting structure concentrates power with the CEO, limiting influence for other shareholders. The 'going concern' warning poses a high risk of losing all investment. Future equity issuances could further dilute holdings.
• **Employees:** The 2025 Share Incentive Plan aims to attract and retain key personnel, potentially benefiting employees through equity awards. However, the company's non-compliance with PRC labor laws regarding social insurance and housing provident funds could lead to penalties and impact employee benefits or job security.
• **Customers (Patients):** Benefit from an expanding online medical services platform, increased access to doctors, and a wider selection of pharmaceutical products. The high patient repurchase rate suggests satisfaction with services. However, potential system failures, security breaches, or issues with doctor quality could negatively impact customer experience and trust.
• **Suppliers:** The company's reliance on a limited number of key suppliers creates a concentration risk for both parties. While the company aims to secure favorable terms, any disruptions could affect supplier relationships and the supply chain.
• **Creditors:** Face risks due to the company's significant working capital deficit and 'going concern' status, which raises doubts about its ability to meet obligations as they become due. Loans from related parties and financial institutions are crucial for liquidity, but their repayment is uncertain given the financial health.

Next Steps

• Launch pilot trial operations for online medical insurance payment in Guangzhou, preparing for expansion to other cities in Guangdong and China.
• Continue to recruit quality doctors onto the platform and attract more patient users.
• Continue to expand and strengthen presence in key cities and provinces across China.
• Continue to enhance supply chain capabilities by expanding product offerings and supplier channels.
• Continue to invest in research and development to enhance technology capabilities, including AI and big data analytics.
• Explore new patient acquisition channels via enhanced B2B collaboration, such as partnerships with insurance companies.
• Utilize accumulated big data to empower the industry by providing clinical data to pharmaceutical companies and insights to commercial insurance companies and governmental authorities.
• Expand experience and reputation in chronic diseases to more medical areas and departments.
• Implement measures to address identified material weaknesses in internal control over financial reporting, including hiring personnel, engaging consultants, and developing policies.
• Complete the necessary government registrations or record-filings for future loans to PRC subsidiaries or VIE or capital contributions to wholly foreign-owned subsidiaries in China.

Key Dates

Recommendation

Despite some operational growth in patient and doctor metrics, the filing presents overwhelming financial and structural risks that warrant a 'strong sell' recommendation. The explicit 'substantial doubt about our ability to continue as a going concern' from the independent auditor is a critical red flag. This is compounded by persistent net losses, a worsening working capital deficit, and negative cash flows from operations. The identified material weaknesses in internal controls indicate fundamental deficiencies in financial reporting and operational oversight. Furthermore, the complex VIE structure in China introduces significant regulatory and enforceability uncertainties, and the dual-class share structure heavily concentrates voting power, limiting minority shareholder influence. The company's reliance on related-party loans and the lack of a clear path to sustained profitability make it a highly speculative and high-risk investment.

Keywords

Online Medical Services, Chronic Disease Management, Digital Healthcare, Pharmaceutical Supply Chain, Internet Hospital, China Healthcare, SEC Filing, IPO, ADS, Nasdaq, VIE Structure, PRC Regulation, Telemedicine, Prescription Drugs, Healthcare Technology